BGOG-en-10

Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

Sponsor:  AstraZeneca

Participating sites:

  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • CHU UCL St-Luc, Bruxelles
  • Hôpital de Libramont, Libramont
  • AZ Groeninge, Kortrijk
  • AZ Sint Jan Brugge, Brugge
  • Grand Hôpital de Charleroi, Charleroi
  • Clinique CHC Montlégia, Liège
  • Jessa Ziekenhuis, Hasselt